Table 4.
Association between molecular marker expressions and clinicopathological features in OSCC patients (n = 97).
| Clinicopathological features | Cyclin-D1 |
EGFR |
p53 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative (n = 13) (%) | Moderate positive (n = 64) (%) | Strong positive (n = 20) (%) | p value | Negative (n = 7) (%) | Moderate positive (n = 59) (%) | Strong positive (n = 31) (%) | p value | Negative (n = 14) (%) | Moderate positive (n = 62) (%) | Strong positive (n = 21) (%) | p value | |
| Grade | ||||||||||||
| MD/PD | 5 (38.5) | 20 (31.3) | 7 (35.0) | 0.861 | 3 (42.9) | 19 (32.2) | 10 (32.3) | 0.847 | 6 (42.9) | 22 (35.5) | 4 (19.0) | 0.267 |
| WD | 8 (61.5) | 44 (68.8) | 13 (65.0) | 4 (57.1) | 40 (67.8) | 21 (67.7) | 8 (57.1) | 40 (64.5) | 17 (81.0) | |||
| Tumor size | ||||||||||||
| T2/T3 | 4 (30.8) | 16 (25.0) | 4 (20.0) | 0.780 | 1 (14.3) | 18 (30.5) | 5 (16.1) | 0.259 | 6 (42.9) | 12 (19.4) | 6 (28.6) | 0.165 |
| T4 | 9 (69.2) | 48 (75.0) | 16 (80.0) | 6 (85.7) | 41 (69.5) | 26 (83.9) | 8 (57.1) | 50 (80.6) | 15 (71.4) | |||
| Nodal status | ||||||||||||
| N0 | 6 (46.2) | 24 (37.5) | 2 (10.0) | 0.041 | 2 (28.6) | 23 (39.0) | 7 (22.6) | 0.281 | 9 (64.3) | 19 (30.6) | 4 (19.0) | 0.017 |
| N1/N2 | 7 (53.8) | 40 (62.5) | 18 (90.0) | 5 (71.4) | 36 (61.0) | 24 (77.4) | 5 (35.7) | 43 (69.4) | 17 (81.0) | |||
| Stage | ||||||||||||
| III | 6 (46.2) | 19 (29.7) | 3 (15.0) | 0.151 | 2 (28.6) | 20 (33.9) | 6 (19.4) | 0.351 | 6 (42.9) | 16 (25.8) | 6 (28.6) | 0.445 |
| IV | 7 (53.8) | 45 (70.3) | 17 (85.0) | 5 (71.4) | 39 (66.1) | 25 (80.6) | 8 (57.1) | 46 (74.2) | 15 (71.4) | |||